Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness against COVID-19: national test-negative case-control study, England
Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness against COVID-19: national test-negative case-control study, England
Abstract Adolescents in the UK were recommended to have their first dose of mRNA vaccine during a period of high community transmission due to the highly transmissible Delta variant, followed by a second dose at an extended interval of 8-12 weeks. We used national SARS-CoV-2 testing, vaccination and hospitalisation data to estimate vaccine effectiveness (VE) using a test-negative case-control design, against PCR-confirmed symptomatic COVID-19 in England. BNT162b2 vaccination in 12-15-year-olds and 16-17-year-olds was associated with lower VE against symptomatic COVID-19 caused by Omicron compared to Delta. Data shows a rapid increase in VE against symptomatic COVID-19 after the second dose for both Delta and Omicron, although this declines to 23% against Omicron after 70+ days. Very high protection was achieved for Delta against hospitalisation after one dose. Our data highlight the importance of the second vaccine dose for protection against symptomatic COVID-19 and raise important questions about the objectives of an adolescent immunisation programme. If prevention of infection is the primary aim, then regular COVID-19 vaccine boosters will be required.
Powell Annabel A、McOwat Kelsey、Saliba Vanessa、Ramsay Mary E、Lopez-Bernal Jamie、Kirsebom Freja、Stowe Julia、Andrews Nick、Ladhani Shamez N
UK Health Security AgencyUK Health Security AgencyUK Health Security AgencyUK Health Security Agency||NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical MedicineUK Health Security Agency||NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine||NIHR Health Protection Research Unit in Respiratory Infections, Imperial College LondonUK Health Security AgencyUK Health Security AgencyUK Health Security Agency||NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical MedicineUK Health Security Agency||Paediatric Infectious Diseases Research Group, St George?ˉs University of London
预防医学医学研究方法医药卫生理论
Powell Annabel A,McOwat Kelsey,Saliba Vanessa,Ramsay Mary E,Lopez-Bernal Jamie,Kirsebom Freja,Stowe Julia,Andrews Nick,Ladhani Shamez N.Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness against COVID-19: national test-negative case-control study, England[EB/OL].(2025-03-28)[2025-08-02].https://www.medrxiv.org/content/10.1101/2021.12.10.21267408.点此复制
评论